Advancing therapeutic development for dry age-related macular degeneration (AMD)
Age-related macular degeneration (AMD) is the leading cause of blindness among white Americans and others of European descent, with lower prevalence among those of Asian, Latino, or African ancestry. The overall prevalence of AMD is approximately 8.7 percent worldwide and is expected to rise to 196...
| Otros Autores: | , |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Washington, D. C. :
the National Academies Press
2015.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009816736806719 |
| Sumario: | Age-related macular degeneration (AMD) is the leading cause of blindness among white Americans and others of European descent, with lower prevalence among those of Asian, Latino, or African ancestry. The overall prevalence of AMD is approximately 8.7 percent worldwide and is expected to rise to 196 million people worldwide by 2020 and 288 million by 2040. AMD typically affects people age 50 and older, and the prevalence increases with age, particularly after the age of 75. In November 2014 the Institute of Medicine's Forum on Neuroscience and Nervous System Disorders hosted a workshop to discuss opportunities for advancing drug development for dry AMD. This report summarizes the presentation and discussion of that workshop. |
|---|---|
| Descripción Física: | 1 online resource (8 pages) : illustrations |
